PRENALTEROL

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H19NO3
Molecular Weight	225.2842
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NC[C@H](O)COC1=CC=C(O)C=C1

InChI

InChIKey=ADUKCCWBEDSMEB-NSHDSACASA-N

InChI=1S/C12H19NO3/c1-9(2)13-7-11(15)8-16-12-5-3-10(14)4-6-12/h3-6,9,11,13-15H,7-8H2,1-2H3/t11-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7270401 | https://www.ncbi.nlm.nih.gov/pubmed/3191661 | https://www.ncbi.nlm.nih.gov/pubmed/2572262

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 163 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1687080\|https://www.ncbi.nlm.nih.gov/pubmed/6131123\|https://www.ncbi.nlm.nih.gov/pubmed/6120845\|https://www.ncbi.nlm.nih.gov/pubmed/2564629	Partial Agonist 297		280.0 nM [Ki]

PubMed

Title	Date	PubMed
Towards a thermodynamic definition of efficacy in partial agonism: The thermodynamics of efficacy and ligand proton transfer in a G protein-coupled receptor of the rhodopsin class.	2010-11-15	20727346
Role of selective alpha and beta adrenergic receptor mechanisms in rat jejunal longitudinal muscle contractility.	2008-06	17879122
beta(2) and beta(3)-adrenoceptor inhibition of alpha(1)-adrenoceptor-stimulated Ca(2+) elevation in human cultured prostatic stromal cells.	2007-09-10	17617401
Recruitment of functionally active heart beta2-adrenoceptors in the initial phase of endotoxic shock in pithed rats.	2006-11	17047523
Positive inotropic and lusitropic effects mediated via the low-affinity state of beta1-adrenoceptors in pithed rats.	2005-11	16151438
Regulation of postburn ischemia by alpha- and beta-adrenoceptor subtypes.	2005-03	15683682
alpha- and beta-adrenergic receptor mechanisms in spontaneous contractile activity of rat ileal longitudinal smooth muscle.	2005-02	15694819
Atypical cardiostimulant beta-adrenoceptor in the rat heart: stereoselective antagonism by bupranolol but lack of effect by some bupranolol analogues.	2003-08	12922943
Ion-selective electrode for the determination of prenalterol.	2003-05-01	18969017
[Monoclonal gammopathy of undetermined significance (MGUS): establishment of premyeloma concept].	2002-07	12229119
Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.	1999-11	10531390
beta1 to beta3 switch in control of cyclic adenosine monophosphate during brown adipocyte development explains distinct beta-adrenoceptor subtype mediation of proliferation and differentiation.	1999-09	10465291
Modulation of inotropic therapy by venodilation in acute heart failure: a randomised comparison of four inotropic agents, alone and combined with isosorbide dinitrate.	1992-01	1375684
Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.	1989-03	2564629
Noninvasive assessment of chronotropic and inotropic response to preferential beta-1 and beta-2 adrenoceptor stimulation.	1984-06	6145533

Patents

Sample Use Guides

In Vivo Use Guide

The eight patients were given prenalterol (PNL) orally, 30 to 200 mg/day, versus placebo for 6 days

Route of Administration: Oral

Name

Type

Language

PRENALTEROL

Official Name

English

(-)-(S)-1-(P-HYDROXYPHENOXY)-3-(ISOPROPYLAMINO)-2-PROPANOL

Preferred Name

English

prenalterol [INN]

Common Name

English

Prenalterol [WHO-DD]

Common Name

English

PRENALTEROL [MI]

Common Name

English

PHENOL, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QC01CA13